The stock price of TC BioPharm (TCBP) closed the recent trading session at $2.12, 50% less than the previous trading session. The stock gained 17.92% to $2.5 in the pre-market. On February 11, 2022, the company got listed on NASDAQ and started trading. TCBP filed the form F-1MEF with the SEC for the addition of the securities to a prior effective registration statement on February 10, 2022.
News
On February 10, 2022, TC BioPharm (TCBP) made an announcement for its initial public offering of 4.11 million shares and warrants for the price of $17.5 million before the underwriting discount, commission, and another cost of the public offerings. Each American Depositary Share (ADS) will represent one normal share and every warrant will act for the purchase of one ADS. ADS and Warrants will be offered to buyers in a mix of one ADS and two Warrants, at a consolidated total price of $4.25. Each Warrant will be promptly exercisable for one share, and the expiry will be after six years of the issue date.
Also, TCBP has conceded the under-writers a 45-day choice to buy up to 0.61 million ADSs as well as warrants to buy up to 1.23 million ADSs, in any mix, at the public share cost per security.
In other news, on February 11, 2022, announced that the ADS which represents the company’s normal share will start trading on NASDAQ under the ticker of “TCBP”. The Chief Executive Officer (CEO) of TC BioPharm, Bryan Kobel, said that listing on NASDAQ is a significant achievement for the company. He added that trading on NASDAQ will award them with admittance to one of the world’s biggest capital markets. This will upgrade their perceivability in the financial center and will unlock the shareholders’ value.
About TCBP
TC BioPharm is a clinical-stage biopharmaceutical organization that focuses on the disclosure, development, and commercialization of gamma-delta T cell treatments for the therapy of cancer and viral diseases. TCBP is headquartered in the United Kingdom (UK).
